首页> 外文期刊>Aging clinical and experimental research >Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study
【24h】

Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study

机译:利拉鲁肽和老年人肥胖症:预防脂肪减少和减少肌肉减少症的功效。透视案例系列研究

获取原文
获取原文并翻译 | 示例
       

摘要

For the growing numbers of obese elderly with diabetes, the glucagon-like peptide-1 (GLP-1) receptor analogue (liraglutide) appears a safe way to promote and maintain substantial weight loss. Given this background, the aim of this study was to assess the effect of the liraglutide treatment, at doses up to 3.0 mg per day, on the body composition, focusing on sarcopenia, in overweight and obese elderly with type 2 diabetes mellitus (T2DM).
机译:对于越来越多的肥胖老年糖尿病患者,胰高血糖素样肽1(GLP-1)受体类似物(利拉鲁肽)似乎是促进和维持明显体重减轻的安全方法。在这种背景下,这项研究的目的是评估每天2毫克以下剂量的利拉鲁肽治疗对超重和肥胖的2型糖尿病(T2DM)老年人的肌肉组成的影响,重点是肌​​肉减少症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号